Harrow lead product misses 4 views
Harrow gets FDA clearance of IND for Phase 3 TRIESENCE trial to treat ocular inflammation and pain after cataract surgery
- FDA IND clearance supports a planned Phase 3 TRIESENCE trial aimed at expanding its label after cataract surgery
- Q4 2025 revenue reached a record $89.1M, up 33% YoY, while EPS $0.17 (-29% YoY) and revenue miss estimates
- Q4 2025 net income was $6.6M, corresponding to diluted EPS of $0.17
- Company guides 2026 revenue to $350–$365M and Adjusted EBITDA to $80–$100M
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.